EFURLAZ Trademark

Trademark Overview

On Thursday, May 15, 2014, a trademark application was filed for EFURLAZ with the United States Patent and Trademark Office. The USPTO has given the EFURLAZ trademark a serial number of 86282494. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, August 30, 2024. This trademark is owned by Glaxo Group Limited. The EFURLAZ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines
efurlaz

General Information

Serial Number86282494
Word MarkEFURLAZ
Filing DateThursday, May 15, 2014
Status710 - CANCELLED - SECTION 8
Status DateFriday, August 30, 2024
Registration Number5404097
Registration DateTuesday, February 20, 2018
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 5, 2017

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, August 30, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGlaxo Group Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS
GB
Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS
Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS

Trademark Events

Event DateEvent Description
Friday, May 30, 2014NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, May 19, 2014NEW APPLICATION ENTERED
Friday, August 29, 2014ASSIGNED TO EXAMINER
Thursday, September 4, 2014SUSPENSION LETTER WRITTEN
Thursday, September 4, 2014NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, September 4, 2014LETTER OF SUSPENSION E-MAILED
Monday, March 30, 2015ASSIGNED TO LIE
Monday, March 30, 2015REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Tuesday, March 31, 2015TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Thursday, April 2, 2015TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, April 2, 2015CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, April 14, 2015SUSPENSION LETTER WRITTEN
Tuesday, April 14, 2015NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, April 14, 2015LETTER OF SUSPENSION E-MAILED
Thursday, November 2, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 15, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 5, 2017PUBLISHED FOR OPPOSITION
Tuesday, December 5, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 20, 2018REGISTERED-PRINCIPAL REGISTER
Friday, October 28, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, June 23, 2015TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, October 14, 2015REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Monday, April 18, 2016REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Tuesday, October 18, 2016REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Monday, April 24, 2017REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Tuesday, October 24, 2017SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Friday, October 28, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, October 28, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, October 28, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, October 28, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, February 20, 2023COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Friday, August 30, 2024CANCELLED SEC. 8 (6-YR)

Related Keywords

efurlaz pharmaceutical treatment disorders preparations substances diseases ophthalmic respiratory hepatological oncological